Literature DB >> 8495605

Relationship between glycemic control and collagen-linked advanced glycosylation end products in type I diabetes.

P J Beisswenger1, L L Moore, T J Curphey.   

Abstract

OBJECTIVE: To evaluate the relationship between glycemic control over a 3-yr period and tissue levels of advanced glycosylation end products. The development of renal failure, blindness, and generalized vascular occlusion continue to be the most serious ravages of diabetes. Tissue glycosylation and AGEs are felt to play an important role in the development of these sequelae, but no data are available on the relationship between AGEs and long-term glycemic control. RESEARCH DESIGN AND METHODS: We studied 48 subjects with type I diabetes. Glycemic control was determined by mean levels of HbA1, and AGEs were determined on collagenase digests of skin collagen by fluorescence at excitation/emission readings of 335/385 and 370/440 nm.
RESULTS: To evaluate the relationship between glycemic control and AGE levels, control was classified as good (< or = 8.5%), fair (> 8.5% but < or = 10%), or poor (> 10%) on the basis of mean HbA1 levels during 1- and 3-yr periods. Analysis of the mean AGE levels for each level of glycemic control over 1-3 yr showed that AGEs differed significantly across categories of glycemic control (P = 0.04 and 0.003), with the lowest AGE levels associated with good and the highest with poor glycemic control. The relationship also was highly significant when adjusted for age, sex, and duration of diabetes, and when examined by Pearson's correlation coefficients (P = 0.02 and 0.008).
CONCLUSIONS: Finding a relationship between glycemic control over 1-3 yr and tissue levels of AGEs suggests that AGEs can be modified and possibly reversed by improved glucose levels.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8495605     DOI: 10.2337/diacare.16.5.689

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  10 in total

1.  Advanced glycosylation end products in skin, serum, saliva and urine and its association with complications of patients with type 2 diabetes mellitus.

Authors:  M E Garay-Sevilla; J C Regalado; J M Malacara; L E Nava; K Wróbel-Zasada; A Castro-Rivas; K Wróbel
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

2.  Advanced glycation end-products and methionine sulphoxide in skin collagen of patients with type 1 diabetes.

Authors:  Y Yu; S R Thorpe; A J Jenkins; J N Shaw; M A Sochaski; D McGee; C E Aston; T J Orchard; N Silvers; Y G Peng; J A McKnight; J W Baynes; T J Lyons
Journal:  Diabetologia       Date:  2006-08-29       Impact factor: 10.122

3.  Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial.

Authors:  V M Monnier; O Bautista; D Kenny; D R Sell; J Fogarty; W Dahms; P A Cleary; J Lachin; S Genuth
Journal:  Diabetes       Date:  1999-04       Impact factor: 9.461

4.  Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes--the EURODIAB Prospective Complications Study.

Authors:  M T Schram; N Chaturvedi; C G Schalkwijk; J H Fuller; C D A Stehouwer
Journal:  Diabetologia       Date:  2005-02-04       Impact factor: 10.122

Review 5.  The pecking order of skin Advanced Glycation Endproducts (AGEs) as long-term markers of glycemic damage and risk factors for micro- and subclinical macrovascular disease progression in Type 1 diabetes.

Authors:  Vincent M Monnier; Saul Genuth; David R Sell
Journal:  Glycoconj J       Date:  2016-06-25       Impact factor: 2.916

6.  Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis.

Authors:  Timothy J Lyons; Alicia J Jenkins
Journal:  Diabetes Rev (Alex)       Date:  1997

7.  The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat.

Authors:  T Soulis-Liparota; M E Cooper; M Dunlop; G Jerums
Journal:  Diabetologia       Date:  1995-04       Impact factor: 10.122

8.  Advanced glycation end products in human diabetic lens capsules.

Authors:  Johanna Rankenberg; Stefan Rakete; Brandie D Wagner; Jennifer L Patnaik; Christian Henning; Anne Lynch; Marcus A Glomb; Ram H Nagaraj
Journal:  Exp Eye Res       Date:  2021-07-21       Impact factor: 3.770

9.  Dietary rapamycin supplementation reverses age-related vascular dysfunction and oxidative stress, while modulating nutrient-sensing, cell cycle, and senescence pathways.

Authors:  Lisa A Lesniewski; Douglas R Seals; Ashley E Walker; Grant D Henson; Mark W Blimline; Daniel W Trott; Gary C Bosshardt; Thomas J LaRocca; Brooke R Lawson; Melanie C Zigler; Anthony J Donato
Journal:  Aging Cell       Date:  2016-09-22       Impact factor: 9.304

10.  Using Skin Bioengineering to Highlight How Weight and Diabetes Mellitus Modify the Skin in the Lower Limbs of Super-Obese Patients.

Authors:  Elisabetta Iacopi; Nicola Riitano; Valentina Dini; Rossana Berta; Letizia Pieruzzi; Agata Janowska; Marco Anselmino; Alberto Piaggesi; Marco Romanelli
Journal:  Diabetes Metab Syndr Obes       Date:  2020-03-16       Impact factor: 3.168

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.